申请人:ONO PHARMACEUTICAL CO., LTD.
公开号:US20180002308A1
公开(公告)日:2018-01-04
A medicinal agent for the prevention and/or treatment of diseases caused by EP
4
receptor activation. A compound having antagonistic activity against the EP
4
receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP
4
receptor for the prevention and/or treatment of diseases caused by EP
4
receptor activation.